BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124. [PMID: 17101615 DOI: 10.1056/nejmoa061254] [Cited by in Crossref: 528] [Cited by in F6Publishing: 83] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Sinning JM, Walenta K, Werner N, Böhm M. Hotline update of clinical trials and registries presented at the 77th spring meeting of the German Society of Cardiology 2011. Clin Res Cardiol 2011;100:553-60. [PMID: 21656190 DOI: 10.1007/s00392-011-0325-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Emter CA, Bowles DK. Store-operated Ca(2+) entry is not essential for PDGF-BB induced phenotype modulation in rat aortic smooth muscle. Cell Calcium 2010;48:10-8. [PMID: 20619453 DOI: 10.1016/j.ceca.2010.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ. 2015;351:h5392. [PMID: 26537292 DOI: 10.1136/bmj.h5392] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
4 Rodrigues H, Gonçalves FB, Alves G, Amaral C, Rodrigues G, Abreu R, Quintas A, Oliveira N, Ferreira ME, Castro JA, Capitão LM. Estenose intra-stent na artéria femoral superficial: Soluções actuais para um problema crescente. Angiologia e Cirurgia Vascular 2013;9:78-83. [DOI: 10.1016/s1646-706x(13)70004-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Chung JH, Lee KE, Her AY, Lee JM, Doh JH, Nam CW, Koo BK, Shin ES. Comparison of fractional flow reserve and angiographic characteristics after balloon angioplasty in de novo coronary lesions. Int J Cardiovasc Imaging 2019;35:1945-54. [PMID: 31214851 DOI: 10.1007/s10554-019-01649-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 2008;28:1084-9. [PMID: 18309114 DOI: 10.1161/ATVBAHA.107.155796] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
7 Meneguz-Moreno RA, Ribamar Costa J Jr, Abizaid A. Drug-Coated Balloons: Hope or Hot Air: Update on the Role of Coronary DCB. Curr Cardiol Rep 2018;20:100. [PMID: 30171374 DOI: 10.1007/s11886-018-1025-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Jim MH, Yiu KH. Combined drug-eluting stent and supplementary paclitaxel-eluting balloon application at side branch ostium for in-stent restenotic true bifurcation lesion. Int J Cardiol 2015;181:149-51. [PMID: 25497542 DOI: 10.1016/j.ijcard.2014.12.033] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Bozsak F, Gonzalez-Rodriguez D, Sternberger Z, Belitz P, Bewley T, Chomaz JM, Barakat AI. Optimization of Drug Delivery by Drug-Eluting Stents. PLoS One. 2015;10:e0130182. [PMID: 26083626 DOI: 10.1371/journal.pone.0130182] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
10 Scheer F, Lüdtke CW, Kamusella P, Wiggermann P, Vieweg H, Schlöricke E, Lichtenberg M, Andresen R, Wissgott C. Combination of rotational atherothrombectomy and Paclitaxel-coated angioplasty for femoropopliteal occlusion. Clin Med Insights Cardiol 2014;8:43-8. [PMID: 25983558 DOI: 10.4137/CMC.S15231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Navarese EP, Austin D, Gurbel PA, Andreotti F, Tantry U, James S, Buffon A, Kozinski M, Obonska K, Bliden K, Jeong YH, Kubica J, Kunadian V. Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res Cardiol 2013;102:279-87. [PMID: 23262495 DOI: 10.1007/s00392-012-0532-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
12 McCutcheon K, Garda R, Mkhwanazi L, Vachiat A, Ramjee R, Moosa J, Tsabedze N, Karolia S, Manga P. Provisional main branch stenting with drug-eluting stents after drug-eluting balloon treatment of the side branch: a simple and durable technique for treating bifurcation lesions. Int J Cardiol 2015;182:294-6. [PMID: 25585366 DOI: 10.1016/j.ijcard.2014.12.132] [Reference Citation Analysis]
13 Kolachalama VB, Pacetti SD, Franses JW, Stankus JJ, Zhao HQ, Shazly T, Nikanorov A, Schwartz LB, Tzafriri AR, Edelman ER. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation 2013;127:2047-55. [PMID: 23584359 DOI: 10.1161/CIRCULATIONAHA.113.002051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 5.1] [Reference Citation Analysis]
14 DeSilvey DL. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Am J Geriatr Cardiol 2007;16:115-6. [PMID: 17342013 DOI: 10.1111/j.1076-7460.2007.06204.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Möllmann H, Szardien S, Kempfert J, Nef H, Liebetrau C, Walther T, Hamm C. [Myocardial revascularization]. Herz 2013;38:513-26; quiz 527-8. [PMID: 23897600 DOI: 10.1007/s00059-013-3917-9] [Reference Citation Analysis]
16 Park SD, Yoon CH, Oh IY, Suh JW, Cho YS, Youn TJ, Choi DJ, Chae IH. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial. Trials 2013;14:38. [PMID: 23394404 DOI: 10.1186/1745-6215-14-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Leitão Marques A. Drug-eluting balloons: the path is made by walking. Rev Port Cardiol 2013;32:371-2. [PMID: 23680480 DOI: 10.1016/j.repc.2013.03.003] [Reference Citation Analysis]
18 Scheller B, Fischer D, Clever YP, Kleber FX, Speck U, Böhm M, Cremers B. Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. Clin Res Cardiol 2013;102:469-72. [PMID: 23512317 DOI: 10.1007/s00392-013-0556-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Redfors B, Généreux P, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, Kirtane AJ, Stone GW. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. Am Heart J 2018;197:142-9. [PMID: 29447774 DOI: 10.1016/j.ahj.2017.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Jim MH, Ho HH, Yiu KH, Siu CW, Chow WH. Angiographic and long-term clinical outcome of the sleeve technique in treating in-stent restenotic bifurcation lesions: a preliminary experience. Acute Card Care 2011;13:159-63. [PMID: 21877875 DOI: 10.3109/17482941.2011.606471] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Varcoe R, Smith W. Use of a cutting balloon and a paclitaxel-coated balloon to treat recurrent subclavian in-stent restenosis causing coronary subclavian steal syndrome. Cardiovasc Revasc Med 2011;12:403-6. [PMID: 21798824 DOI: 10.1016/j.carrev.2011.04.004] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81. [PMID: 18536865 DOI: 10.1007/s00392-008-0682-5] [Cited by in Crossref: 190] [Cited by in F6Publishing: 126] [Article Influence: 13.6] [Reference Citation Analysis]
23 Yang K, Fang S, Zhang X, Wang T, Feng Y, Jiao L, Yan Y. In-stent restenosis after vertebral artery origin stenosis stenting: a nomogram for risk assessment. J Neurointerv Surg 2022:neurintsurg-2022-019091. [PMID: 35896318 DOI: 10.1136/neurintsurg-2022-019091] [Reference Citation Analysis]
24 Chen Y, Hu S, Wu L. Drug-eluting balloon for instent restenosis. Heart 2013;99:1874. [PMID: 23955719 DOI: 10.1136/heartjnl-2013-304720] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Sato A, Kijima M, Ichimura S, Yaegashi D, Anzai F, Shimizu T, Matsui Y, Kaneko H, Sakamoto K, Seino Y, Maruyama Y, Takeishi Y. Short-term outcome of percutaneous coronary intervention with directional coronary atherectomy followed by drug-coated balloon: a preliminary report. Cardiovasc Interv Ther 2019;34:149-54. [PMID: 29987653 DOI: 10.1007/s12928-018-0537-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 Chae IH, Yoon CH, Park JJ, Oh IY, Suh JW, Cho YS, Youn TJ, Choi DJ. Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. J Korean Med Sci 2017;32:933-41. [PMID: 28480650 DOI: 10.3346/jkms.2017.32.6.933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang Y, Zhang X, Dong Q, Chen D, Xu Y, Jiang J. Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon. Front Cardiovasc Med 2021;8:762391. [PMID: 34926613 DOI: 10.3389/fcvm.2021.762391] [Reference Citation Analysis]
28 Sun S, Zhang Q, Wang Q, Wu Q, Xu G, Chang P, Hu H, Bai F. Local delivery of thalidomide to inhibit neointima formation in rat model with artery injury. Pathol Res Pract 2018;214:1303-8. [PMID: 30029933 DOI: 10.1016/j.prp.2018.02.019] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Jim MH. Side branch ostium stenting with main vessel drug-eluting balloon kissing (BOMB): an innovative approach for isolated coronary stenosis at side branch ostium. Int J Cardiol 2013;168:4939-40. [PMID: 23907034 DOI: 10.1016/j.ijcard.2013.07.084] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Wang X, Lu W, Wang X, Pan L, Fu W, Liu Q, Han Z, Sun G, Qin X, Li R, Zheng X, Shan Y, Qiu C. Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis. Int J Cardiovasc Imaging 2020;36:171-8. [PMID: 31919705 DOI: 10.1007/s10554-019-01681-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
31 Pal N, Din J, O'Kane P. Contemporary Management of Stent Failure: Part One. Interv Cardiol 2019;14:10-6. [PMID: 30858886 DOI: 10.15420/icr.2018.39.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
32 Ho HH, Ooi YW, Loh KK, Tan J, Aung TH, Jafary FH, Ong PJL. Clinical Efficacy and Safety of SeQuent Please Paclitaxel-Eluting Balloon in a Real-World Single-Center Registry of South-East Asian Patients. Int J Cardiol Heart Vessel 2013;1:37-41. [PMID: 29450156 DOI: 10.1016/j.ijchv.2013.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
33 Lee K, Lee SG, Jang I, Park SH, Yang D, Seo IH, Bong SK, An DH, Lee MK, Jung IK, Jang YH, Kim JS, Ryu W. Linear Micro-patterned Drug Eluting Balloon (LMDEB) for Enhanced Endovascular Drug Delivery. Sci Rep 2018;8:3666. [PMID: 29507314 DOI: 10.1038/s41598-018-21649-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 van Ditzhuijzen NS, Regar E. Shedding light on in-stent restenosis: are bioresorbable vascular scaffolds the solution for a vexing problem? Can J Cardiol 2015;31:253-4. [PMID: 25660153 DOI: 10.1016/j.cjca.2015.01.003] [Reference Citation Analysis]
35 Joost A, Kurowski V, Radke PW. Drug eluting balloons for the treatment of coronary artery disease: What can we expect? World J Cardiol 2010; 2(9): 257-261 [PMID: 21160601 DOI: 10.4330/wjc.v2.i9.257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
36 Mahmood Zuhdi AS, Zeymer U, Waliszewski M, Spiecker M, Ismail MD, Boxberger M, Ferrari M, Zainal Abidin I, Wan Ahmad WA. The use of paclitaxel coated balloon (PCB) in acute coronary syndrome of small vessel de novo lesions: an analysis of a prospective 'real world' registry. Springerplus 2016;5:373. [PMID: 27066381 DOI: 10.1186/s40064-016-2014-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Nikol S. Gene therapy for coronary and peripheral artery disease. Expert Opinion on Therapeutic Patents 2008;18:903-27. [DOI: 10.1517/13543776.18.8.903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Shibui T, Tsuchiyama T, Masuda S, Nagamine S. Excimer laser coronary atherectomy prior to paclitaxel-coated balloon angioplasty for de novo coronary artery lesions. Lasers Med Sci 2021;36:111-7. [PMID: 32304003 DOI: 10.1007/s10103-020-03019-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Kang E, Robinson J, Park K, Cheng JX. Paclitaxel distribution in poly(ethylene glycol)/poly(lactide-co-glycolic acid) blends and its release visualized by coherent anti-Stokes Raman scattering microscopy. J Control Release 2007;122:261-8. [PMID: 17574291 DOI: 10.1016/j.jconrel.2007.05.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
40 Ierardi AM, Franchin M, Fontana F, Piffaretti G, Duka E, Tonolini M, Miele V, Tozzi M, Carrafiello G. Usefulness of paclitaxel-releasing high-pressure balloon associated with cutting balloon angioplasty for treatment of outflow stenoses of failing hemodialysis arteriovenous shunts. Radiol Med 2017;122:69-76. [PMID: 27601144 DOI: 10.1007/s11547-016-0680-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Jukema JW, Ahmed TA, Verschuren JJ, Quax PH. Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol 2011;9:79-90. [PMID: 21989052 DOI: 10.1038/nrcardio.2011.148] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
42 Colleran R, Kastrati A. Percutaneous coronary intervention: balloons, stents and scaffolds. Clin Res Cardiol 2018;107:55-63. [PMID: 30039189 DOI: 10.1007/s00392-018-1328-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Hu H, Shen L. Drug-coated balloons in the treatment of acute myocardial infarction (Review). Exp Ther Med 2021;21:464. [PMID: 33747196 DOI: 10.3892/etm.2021.9895] [Reference Citation Analysis]
44 Zhao K, Yan P, Wang X, Zhao Y, Li S, Xue Y, Liu X, Li J, Sun Q. A retrospective study of drug-coated balloon angioplasty for vertebral artery origin stenosis. Neuroradiology 2022. [PMID: 35257205 DOI: 10.1007/s00234-022-02926-9] [Reference Citation Analysis]
45 Parikh RB, Victor V, Levy MS. Catheter based interventions for lower extremity peripheral artery disease. Prog Cardiovasc Dis 2021:S0033-0620(21)00127-4. [PMID: 34813857 DOI: 10.1016/j.pcad.2021.11.008] [Reference Citation Analysis]
46 Gao L, Chen YD. Application of drug-coated balloon in coronary artery intervention: challenges and opportunities. J Geriatr Cardiol 2016;13:906-13. [PMID: 28133467 DOI: 10.11909/j.issn.1671-5411.2016.11.005] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
47 Sato T, Tsuchida K, Yuasa S, Taya Y, Koshikawa T, Tanaka K, Fujita S, Ikeda Y, Takahashi M, Okabe M, Oda H, Aizawa Y. The effect of the debulking by excimer laser coronary angioplasty on long-term outcome compared with drug-coating balloon: insights from optical frequency domain imaging analysis. Lasers Med Sci 2020;35:403-12. [PMID: 31264007 DOI: 10.1007/s10103-019-02833-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol 2012;101:573-84. [PMID: 22350752 DOI: 10.1007/s00392-012-0428-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
49 Wong SY, Moskowitz JS, Veselinovic J, Rosario RA, Timachova K, Blaisse MR, Fuller RC, Klibanov AM, Hammond PT. Dual functional polyelectrolyte multilayer coatings for implants: permanent microbicidal base with controlled release of therapeutic agents. J Am Chem Soc 2010;132:17840-8. [PMID: 21105659 DOI: 10.1021/ja106288c] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
50 Pavo N, Samaha E, Sabdyusheva I, von Strandmann RP, Stahnke S, Plass CA, Zlabinger K, Lukovic D, Jambrik Z, Pavo IJ, Bergler-Klein J, Gray WA, Maurer G, Gyöngyösi M. Coating of intravascular balloon with paclitaxel prevents constrictive remodeling of the dilated porcine femoral artery due to inhibition of intimal and media fibrosis. J Mater Sci Mater Med 2016;27:131. [PMID: 27388164 DOI: 10.1007/s10856-016-5737-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
51 Saha R, Mandal PK. Effect of flow pulsatility and time-dependent release kinetics on stent-based delivery through atherosclerotic plaque. Int J Dynam Control 2018;6:1-13. [DOI: 10.1007/s40435-016-0289-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
52 Waksman R, Epstein SE. Prednisone: the last gasp of immunosuppresive therapy for restenosis prevention. Eur Heart J 2013;34:1702-4. [PMID: 23571835 DOI: 10.1093/eurheartj/eht125] [Reference Citation Analysis]
53 Escuer J, Schmidt AF, Peña E, Martínez MA, Mcginty S. Mathematical modelling of endovascular drug delivery: balloons versus stents. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121742] [Reference Citation Analysis]
54 Peng N, Liu W, Li Z, Wei J, Chen X, Wang W, Lin H. Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials. Cardiovasc Ther 2020;2020:1042329. [PMID: 32411298 DOI: 10.1155/2020/1042329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Müller MJ, Krause U, Paul T, Schneider HE. Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection. Pediatr Cardiol 2011;32:1036-9. [PMID: 21796444 DOI: 10.1007/s00246-011-0054-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
56 Iyer R, Kuriakose AE, Yaman S, Su LC, Shan D, Yang J, Liao J, Tang L, Banerjee S, Xu H, Nguyen KT. Nanoparticle eluting-angioplasty balloons to treat cardiovascular diseases. Int J Pharm 2019;554:212-23. [PMID: 30408532 DOI: 10.1016/j.ijpharm.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Park K, Kim TE, Park KW, Kang HJ, Koo BK, Kim HS. Analysis of potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease. Korean Circ J 2011;41:705-11. [PMID: 22259600 DOI: 10.4070/kcj.2011.41.12.705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Butman SM. In early returns scoring scores big. Catheter Cardiovasc Interv 2016;88:60-1. [PMID: 27400636 DOI: 10.1002/ccd.26642] [Reference Citation Analysis]
59 Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Böhm M, Scheller B. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol 2012;101:469-76. [PMID: 22293991 DOI: 10.1007/s00392-012-0415-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
60 Mok KH, Wickramarachchi U, Watson T, Ho HH, Eccleshall S, Ong PJL. Safety of bailout stenting after paclitaxel-coated balloon angioplasty. Herz 2017;42:684-9. [PMID: 27858114 DOI: 10.1007/s00059-016-4502-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
61 Berg MC, Kolodziej H, Cremers B, Gershony G, Speck U. Drug-Coated Angioplasty Balloon Catheters: Coating Compositions and Methods. Adv Eng Mater 2012;14:B45-50. [DOI: 10.1002/adem.201180067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
62 Alfonso F, Pérez Vizcayno MJ, Cárdenas A, García Del Blanco B, García-Touchard A, López-Minguez JR. Reply: Drug-Coated Balloon Treatment as Default Strategy for DES-ISR. J Am Coll Cardiol 2016;67:348-9. [PMID: 26796404 DOI: 10.1016/j.jacc.2015.11.012] [Reference Citation Analysis]
63 Akin I, Nienaber CA. Treatment of coronary in-stent restenosis-evidence for universal recommendation? J Thorac Dis 2015;7:1672-5. [PMID: 26623079 DOI: 10.3978/j.issn.2072-1439.2015.10.16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Granada JF, Stenoien M, Buszman PP, Tellez A, Langanki D, Kaluza GL, Leon MB, Gray W, Jaff MR, Schwartz RS. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart 2014;1:e000117. [PMID: 25332821 DOI: 10.1136/openhrt-2014-000117] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
65 Räthel T, Mannell H, Pircher J, Gleich B, Pohl U, Krötz F. Magnetic stents retain nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. Pharm Res 2012;29:1295-307. [PMID: 22189692 DOI: 10.1007/s11095-011-0643-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
66 Burzotta F, Brancati MF, Trani C, Porto I, Tommasino A, De Maria G, Niccoli G, Leone AM, Coluccia V, Schiavoni G, Crea F. INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial. Trials 2012;13:55. [PMID: 22559260 DOI: 10.1186/1745-6215-13-55] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
67 Traxler D, Hemetsberger R, Spannbauer A, Zlabinger K, Gugerell A, Lukovic D, Mandic L, Pavo N, Winkler J, Gyöngyösi M. Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries. Histol Histopathol 2020;35:653-63. [PMID: 31646547 DOI: 10.14670/HH-18-177] [Reference Citation Analysis]
68 Cai X, Tian F, Jing J, Jin Q, Zhou S, Yin W, Chen Y, Wu Q, Fu Z, Chen Y. Prognostic value of quantitative flow ratio measured immediately after drug-coated balloon angioplasty for in-stent restenosis. Catheter Cardiovasc Interv 2021;97 Suppl 2:1048-54. [PMID: 33742738 DOI: 10.1002/ccd.29640] [Reference Citation Analysis]
69 Wong YTA, Kang DY, Lee JB, Rha SW, Hong YJ, Shin ES, Her SH, Nam CW, Chung WY, Kim MH, Lee CH, Lee PH, Ahn JM, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. Am Heart J 2018;197:35-42. [PMID: 29447782 DOI: 10.1016/j.ahj.2017.11.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
70 Uhm JS, Chung WS, Lee SJ, Shin AY, Jung SY, Kim CJ, Seo SM, Park HJ, Kim PJ, Chang K, Seung KB. Two cases of percutaneous intervention for coronary artery bypass graft anastomoses with Paclitaxel-eluting balloon catheters. Korean Circ J 2011;41:685-8. [PMID: 22194767 DOI: 10.4070/kcj.2011.41.11.685] [Reference Citation Analysis]
71 Bonvini R, Roffi M, Righini M. Nouvelles techniques endovasculaires dans le traitement de l’artériopathie des membres inférieurs. Journal des Maladies Vasculaires 2011;36:16-23. [DOI: 10.1016/j.jmv.2010.10.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Marquis-Gravel G, Matteau A, Potter BJ, Gobeil F, Noiseux N, Stevens LM, Mansour S. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population. Arq Bras Cardiol 2017;109:277-83. [PMID: 28977052 DOI: 10.5935/abc.20170142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis 2016;8:E1150-62. [PMID: 27867580 DOI: 10.21037/jtd.2016.10.93] [Cited by in Crossref: 109] [Cited by in F6Publishing: 78] [Article Influence: 18.2] [Reference Citation Analysis]
74 Yu X, Ji F, Xu F, Zhang W, Wang X, Lu D, Yang C, Wang F. Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute. Clin Res Cardiol 2019;108:234-43. [PMID: 30074078 DOI: 10.1007/s00392-018-1346-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
75 Gao Z, Xu B, Yang YJ, Yuan JQ, Chen J, Chen JL, Qiao SB, Wu YJ, Yan HB, Gao RL. Long-term outcomes of drug-eluting stent therapy for in-stent restenosis versus de novo lesions. J Interv Cardiol 2013;26:550-5. [PMID: 24118174 DOI: 10.1111/joic.12069] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Quarterman JC, Geary SM, Salem AK. Evolution of drug-eluting biomedical implants for sustained drug delivery. Eur J Pharm Biopharm 2021;159:21-35. [PMID: 33338604 DOI: 10.1016/j.ejpb.2020.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
77 Liao MT, Chen MK, Hsieh MY, Yeh NL, Chien KL, Lin CC, Wu CC, Chie WC. Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2020;15:e0231463. [PMID: 32287283 DOI: 10.1371/journal.pone.0231463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
78 Saha R, Mandal PK. Effects of Interstrut Distance on the Transport of Drug and its Retention in the Arterial Tissue. Int J Appl Comput Math 2017;3:2039-54. [DOI: 10.1007/s40819-016-0223-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Colombo A, Ruparelia N. Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis? J Am Coll Cardiol 2015;66:34-6. [PMID: 26139055 DOI: 10.1016/j.jacc.2015.04.055] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Sella G, Gandelman G, Teodorovich N, Tuvali O, Ayyad O, Abu Khadija H, Haberman D, Poles L, Jonas M, Volodarsky I, George J, Blatt A. Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease. JCM 2022;11:1859. [DOI: 10.3390/jcm11071859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Zhang DM, Chen S. In-Stent Restenosis and a Drug-Coated Balloon: Insights from a Clinical Therapeutic Strategy on Coronary Artery Diseases. Cardiol Res Pract 2020;2020:8104939. [PMID: 33163230 DOI: 10.1155/2020/8104939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Xia C, Jiang Y, Li S, Xiong D, Chen X, Chen Y. In Vitro and In Vivo Comparative Evaluation of a Shellac-Ammonium Paclitaxel-Coated Balloon versus a Benchmark Device. J Interv Cardiol 2021;2021:9962313. [PMID: 34121951 DOI: 10.1155/2021/9962313] [Reference Citation Analysis]
83 Liu L, Liu B, Ren J, Hui G, Qi C, Wang J. Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018;18:46. [PMID: 29499651 DOI: 10.1186/s12872-018-0771-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
84 Schorn I, Malinoff H, Anderson S, Lecy C, Wang J, Giorgianni J, Papandreou G. The Lutonix® drug-coated balloon: A novel drug delivery technology for the treatment of vascular disease. Adv Drug Deliv Rev 2017;112:78-87. [PMID: 28559093 DOI: 10.1016/j.addr.2017.05.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
85 Rivero F, Cuesta J, Bastante T, García-Guimaraes M, Alfonso F. Treatment options for stent restenosis: insights from intracoronary imaging, clinical trials, and registries. Coron Artery Dis 2017;28:507-17. [PMID: 28562383 DOI: 10.1097/MCA.0000000000000511] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Gao Z, Yang Y, Xu B, Chen J, Qiao S, Li J, Wu Y, Qin X, Yuan J, Gao R. Three year follow-up of the sirolimus-eluting stent and the paclitaxel-eluting stent in daily practice. Clin Cardiol 2009;32:E63-7. [PMID: 20014187 DOI: 10.1002/clc.20550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Rottbauer W, Katus HA. [Patients with coronary artery stents: when and how should operations be carried out?]. Chirurg 2009;80:515-8. [PMID: 19436961 DOI: 10.1007/s00104-008-1659-7] [Reference Citation Analysis]
88 Kufner S, Rai H, Wiebe J, Altevogt F, Pyxaras S, Joner M, Xhepa E, Cassese S, Colleran R, Schunkert H, Zrenner B, Kastrati A, Byrne RA; Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3A (ISAR-DESIRE 3A) Investigators. A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-DESIRE 3A). Catheter Cardiovasc Interv 2021. [PMID: 34791755 DOI: 10.1002/ccd.30014] [Reference Citation Analysis]
89 Sheiban I, Anselmino M, Moretti C, Biondi-Zoccai G, Galloni M, Vignolini C, Mattoni M, Sciuto F, Omedè P, Trevi GP. Effect of a novel drug-eluted balloon coated with genistein before stent implantation in porcine coronary arteries. Clin Res Cardiol 2008;97:891-8. [PMID: 18777002 DOI: 10.1007/s00392-008-0705-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
90 Pleva L, Kukla P, Zapletalova J, Hlinomaz O. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. BMC Cardiovasc Disord 2017;17:168. [PMID: 28651572 DOI: 10.1186/s12872-017-0602-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
91 Scheller B, Speck U, Böhm M. Prevention of restenosis: is angioplasty the answer? Heart 2007;93:539-41. [PMID: 17435062 DOI: 10.1136/hrt.2007.118059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
92 Nicolais C, Lakhter V, Virk HUH, Sardar P, Bavishi C, O'Murchu B, Chatterjee S. Therapeutic Options for In-Stent Restenosis. Curr Cardiol Rep 2018;20:7. [PMID: 29435779 DOI: 10.1007/s11886-018-0952-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
93 Nestelberger T, Jeger R. Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review. Interv Cardiol 2019;14:131-6. [PMID: 31867057 DOI: 10.15420/icr.2019.06.R3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Solomonica A, Musallam A, Roguin A. Coronary artery aneurysm following drug-coated balloon treatment. Cardiovasc Revasc Med 2015;16:505-7. [PMID: 26349442 DOI: 10.1016/j.carrev.2015.08.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
95 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
96 Lee CW, Park SJ. Drug-eluting balloon: early enthusiasm being tempered by growing uncertainty. Coron Artery Dis 2016;27:78-9. [PMID: 26829455 DOI: 10.1097/MCA.0000000000000313] [Reference Citation Analysis]
97 Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, Cremers B, Hardt S, Buerke M, Ackermann H, Boxberger M, Degenhardt R, Scheller B. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2010;99:165-74. [PMID: 20052480 DOI: 10.1007/s00392-009-0101-6] [Cited by in Crossref: 138] [Cited by in F6Publishing: 95] [Article Influence: 11.5] [Reference Citation Analysis]
98 Pleva L, Kukla P, Zapletalová J, Hlinomaz O. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. Cor Vasa 2021;63:442-7. [DOI: 10.33678/cor.2021.013] [Reference Citation Analysis]
99 Zhu Z, Han H, Zhu J, Zhang J, Du R, Ni J, Ying C, An X, Zhang R. Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Biomed Mater Eng 2015;26:79-88. [PMID: 26484558 DOI: 10.3233/BME-151551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Peterson S, Hasenbank M, Silvestro C, Raina S. IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease. Adv Drug Deliv Rev 2017;112:69-77. [PMID: 27771367 DOI: 10.1016/j.addr.2016.10.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
101 Hüsing A, Reinecke H, Cicinnati VR, Beckebaum S, Wilms C, Schmidt HH, Kabar I. Paclitaxel-eluting balloon dilation of biliary anastomotic stricture after liver transplantation. World J Gastroenterol 2015; 21(3): 977-981 [PMID: 25624733 DOI: 10.3748/wjg.v21.i3.977] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
102 Scott RA, Panitch A. Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention. Biomacromolecules 2014;15:2825-32. [PMID: 24964369 DOI: 10.1021/bm5007757] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
103 Gemeinhardt O, Schnorr B, Speck U, Scheller B. A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions. PLoS One 2021;16:e0259106. [PMID: 34714843 DOI: 10.1371/journal.pone.0259106] [Reference Citation Analysis]
104 Tzafriri AR, Levin AD, Edelman ER. Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery. Cell Prolif 2009;42:348-63. [PMID: 19438899 DOI: 10.1111/j.1365-2184.2009.00602.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
105 Nijhoff F, Stella PR, Troost MS, Belkacemi A, Nathoe HM, Voskuil M, Samim M, Doevendans PA, Agostoni P. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. Clin Res Cardiol 2016;105:401-11. [PMID: 26541146 DOI: 10.1007/s00392-015-0934-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
106 Ito N, Takahara M, Soga Y, Hiramori S, Hirose K, Tomoi Y, Ando K. Lumen Loss at 1 Year After Bare Nitinol Stent Implantation in the Superficial Femoral Artery. J Endovasc Ther 2021;28:132-8. [PMID: 32813594 DOI: 10.1177/1526602820950261] [Reference Citation Analysis]
107 Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15:173-184. [PMID: 29662511 DOI: 10.11909/j.issn.1671-5411.2018.02.007] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
108 Dorenkamp M, Boldt J, Leber AW, Sohns C, Roser M, Boldt LH, Haverkamp W, Bonaventura K. Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis. Clin Cardiol 2013;36:407-13. [PMID: 23595957 DOI: 10.1002/clc.22130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
109 Sabaté M. Sirolimus Versus Paclitaxel: Second Round. JACC Cardiovasc Interv 2022;15:780-2. [PMID: 35305907 DOI: 10.1016/j.jcin.2022.02.007] [Reference Citation Analysis]
110 Möllmann H, Szardien S, Kempfert J, Nef H, Liebetrau C, Walther T, Hamm C. [Myocardial revascularization]. Internist (Berl) 2012;53:1063-75; quiz 1076-8. [PMID: 22836917 DOI: 10.1007/s00108-012-3035-4] [Reference Citation Analysis]
111 Pöss J, Jacobshagen C, Ukena C, Böhm M. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010;99:411-7. [PMID: 20499071 DOI: 10.1007/s00392-010-0176-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
112 Granada JF, Virmani R, Schulz-jander D, Tunev S, Melder RJ. Rate of Drug Coating Dissolution Determines In-Tissue Drug Retention and Durability of Biological Efficacy. Journal of Drug Delivery 2019;2019:1-7. [DOI: 10.1155/2019/9560592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
113 Tang J, Hou H, Chu J, Chen F, Yao Y, Gao Y, Ye Z, Zhuang S, Lai Y, Liu X. Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis. Clin Cardiol 2021;44:978-86. [PMID: 34009672 DOI: 10.1002/clc.23630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Hehrlein C. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs. Catheter Cardiovasc Interv 2015;86:287-8. [PMID: 26198065 DOI: 10.1002/ccd.26091] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Burzotta F, Brancati MF, Trani C, Pirozzolo G, De Maria G, Leone AM, Niccoli G, Porto I, Prati F, Crea F. Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial. Heart Vessels 2016;31:677-86. [PMID: 25863804 DOI: 10.1007/s00380-015-0671-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
116 Gilgen N, Farah A, Scheller B, Ohlow MA, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, Zweiker R, Krackhardt F, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan FP, Coslovsky M, Jeger R; BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. Clin Cardiol 2018;41:569-75. [PMID: 29527709 DOI: 10.1002/clc.22942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
117 Cyrus T, Wickline SA, Lanza GM. Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012;4:82-95. [PMID: 21748858 DOI: 10.1002/wnan.154] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
118 Chowdhury MM, Singh K, Albaghdadi MS, Khraishah H, Mauskapf A, Kessinger CW, Osborn EA, Kellnberger S, Piao Z, Lino Cardenas CL, Grau MS, Jaff MR, Rosenfield K, Libby P, Edelman ER, Lindsay ME, Tearney GJ, Jaffer FA. Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits. JACC Basic Transl Sci 2020;5:685-95. [PMID: 32760856 DOI: 10.1016/j.jacbts.2020.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Stolzenburg N, Breinl J, Bienek S, Jaguszewski M, Löchel M, Taupitz M, Speck U, Wagner S, Schnorr J. Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries - First Experimental Results in Rabbits at Low Inflation Pressure. Cardiovasc Drugs Ther 2016;30:263-70. [PMID: 27033233 DOI: 10.1007/s10557-016-6658-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
120 Her AY, Shin ES. Current Management of In-Stent Restenosis. Korean Circ J. 2018;48:337-349. [PMID: 29737639 DOI: 10.4070/kcj.2018.0103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
121 Mehrotra S, Paramasivam G, Mishra S. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. Curr Cardiol Rep 2017;19:10. [PMID: 28185166 DOI: 10.1007/s11886-017-0823-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
122 Kaul U, Unverdorben M, Degenhardt R, Seth A, Bahl VK, Hiremath SM, Chandra P, Mullesari AS, Sandhu PS, Rao S, George O, Ackermann H, Boxberger M. The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study. Indian Heart J 2013;65:510-7. [PMID: 24206873 DOI: 10.1016/j.ihj.2013.08.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
123 Pan L, Lu W, Han Z, Pan S, Wang X, Shan Y, Wang X, Zheng X, Li R, Zhou Y, Qin P, Shi Q, Zhou S, Zhang W, Guo S, Zhang P, Qin X, Sun G, Qin Z, Huang Z, Qiu C. Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study. Clin Res Cardiol 2021. [PMID: 34313800 DOI: 10.1007/s00392-021-01895-y] [Reference Citation Analysis]
124 Ann SH, Balbir Singh G, Lim KH, Koo BK, Shin ES. Anatomical and Physiological Changes after Paclitaxel-Coated Balloon for Atherosclerotic De Novo Coronary Lesions: Serial IVUS-VH and FFR Study. PLoS One 2016;11:e0147057. [PMID: 26824602 DOI: 10.1371/journal.pone.0147057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
125 Kirigaya H, Okada K, Hibi K, Maejima N, Iwahashi N, Matsuzawa Y, Minamimoto Y, Kosuge M, Ebina T, Tamura K, Kimura K. Post-procedural quantitative flow ratio gradient and target lesion revascularization after drug-coated balloon or plain-old balloon angioplasty. Journal of Cardiology 2022. [DOI: 10.1016/j.jjcc.2022.07.007] [Reference Citation Analysis]
126 Her AY, Shin ES, Bang LH, Nuruddin AA, Tang Q, Hsieh IC, Hsu JC, Kiam OT, Qiu C, Qian J, Ahmad WAW, Ali RM. Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group. Cardiol J 2021;28:136-49. [PMID: 31565793 DOI: 10.5603/CJ.a2019.0093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
127 Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23. [PMID: 35656726 DOI: 10.4244/EIJ-D-21-01034] [Reference Citation Analysis]
128 Lee HF, Cheng YW, Peng JR, Hsu CY, Yang CH, Chan YH, Chu PH. Impact of chronic kidney disease on long-term outcomes for coronary in-stent restenosis after drug-coated balloon angioplasty. J Cardiol 2021;78:564-70. [PMID: 34454808 DOI: 10.1016/j.jjcc.2021.08.010] [Reference Citation Analysis]
129 Ribeiro HB. Drug-eluting balloons: an essential tool for contemporary coronary intervention. Coron Artery Dis 2018;29:526-7. [PMID: 30067579 DOI: 10.1097/MCA.0000000000000637] [Reference Citation Analysis]
130 Zhu J, Liu L, Zhu Z, Yang Z, Hu J, Ding F, Zhou Y, Su X, Ge J, Liu X, Tang L, He Y, Zhou G, Ji Z, Li Y, Pang W, Zhang R. A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis. Coron Artery Dis 2021;32:526-33. [PMID: 33229940 DOI: 10.1097/MCA.0000000000000994] [Reference Citation Analysis]
131 Dan K, Sanz Sánchez J, Garcia-Garcia HM. Drug-Coated Balloons for Coronary Artery Disease: First New-Generation Comparison of a Non-Widespread Technology. Cardiovasc Revasc Med 2021;28:7-8. [PMID: 34090793 DOI: 10.1016/j.carrev.2021.05.024] [Reference Citation Analysis]
132 Oh PC, Suh SY, Kang WC, Lee K, Han SH, Ahn T, Shin EK. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty. Korean J Intern Med 2016;31:501-6. [PMID: 26951915 DOI: 10.3904/kjim.2014.189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
133 Wang Y, Lou X, Xu X, Zhu J, Shang Y. Drug-eluting balloons versus drug-eluting stents for the management of in-stent restenosis: A meta-analysis of randomized and observational studies. J Cardiol 2017;70:446-53. [PMID: 28259383 DOI: 10.1016/j.jjcc.2016.12.019] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
134 Liu W, Zhang M, Chen G, Li Z, Wei F. Drug-Coated Balloon for De Novo Coronary Artery Lesions: A Systematic Review and Trial Sequential Meta-analysis of Randomized Controlled Trials. Cardiovasc Ther. 2020;2020:4158363. [PMID: 32934664 DOI: 10.1155/2020/4158363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Elwany M, Di Palma G, Cortese B. Long-term efficacy of drug-coated balloon for renal artery in-stent restenosis. Egypt Heart J 2018;70:55-6. [PMID: 29622999 DOI: 10.1016/j.ehj.2017.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 O'Neill SM, Olympia DK, Fox TE, Brown JT, Stover TC, Houck KL, Wilson R, Waybill P, Kozak M, Levison SW, Weber N, Karavodin LM, Kester M. C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries. Vasc Dis Prev 2008;5:200-10. [PMID: 19946459 DOI: 10.2174/156727008785133809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
137 Kammerer T, Beiras-Fernandez A, Rehm M, Stangl M, Guba M, Kupatt-Jeremias C, Weis F. Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation. BMC Cardiovasc Disord 2014;14:112. [PMID: 25179749 DOI: 10.1186/1471-2261-14-112] [Reference Citation Analysis]
138 Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, Kini A, Sharma SK. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;80:348-72. [PMID: 35863852 DOI: 10.1016/j.jacc.2022.05.017] [Reference Citation Analysis]
139 Li J, Liu WL, Yi X, Feng GK, Lu Z, Jiang XJ, Li XY. Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data. Exp Ther Med 2015;9:2285-92. [PMID: 26136975 DOI: 10.3892/etm.2015.2431] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Seidlitz A, Kotzan N, Nagel S, Reske T, Grabow N, Harder C, Petersen S, Sternberg K, Weitschies W. In vitro determination of drug transfer from drug-coated balloons. PLoS One 2013;8:e83992. [PMID: 24391863 DOI: 10.1371/journal.pone.0083992] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]